Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements [Yahoo! Finance]
Estrella Immunopharma, Inc. (ESLA)
Company Research
Source: Yahoo! Finance
clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC ("Nasdaq"). This confirmation follows the Company's successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates. Specifically, on September 23, 2025, the Company received two letters from the Listing Qualifications Department of Nasdaq. The first letter confirmed the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The second letter confirmed the Company complies with the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). Nasdaq has advised that both matters are now closed.
Show less
Read more
Impact Snapshot
Event Time:
ESLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESLA alerts
High impacting Estrella Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
ESLA
News
- Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB RecommendationBusiness Wire
- Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ESLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ESLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.MarketBeat
- Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable PatientsBusiness Wire
ESLA
Sec Filings
- 12/4/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/6/25 - Form 8-K
- ESLA's page on the SEC website